N-3-Acetyl-2-Hydroxyphenyl Acetamide

103205-33-0

Chenglian Pharmaceutical is an innovative high-tec¶h pharmaceutical enterprise that is market-oriented and realizes industrial  development through R&D innovation and technology trβansformation.

key word:

innovative Pharmaceutical

Category:

Consulting

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to✘ build a large health industry finance platform company integ♥rating pharmaceutical, intelligent medical, bio pharmaceutical R&D, industrial production and© sales.

The chemical reactions involved in the existing products  include Foucault reaction, nitration reaction, sulfonation reaction, hyd​rogenation reaction, fluorination reaction, chlorina‍tion reaction, bromination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor developed by Merck. In October• 2006, Sitagliptin phosphate Januvia was approved by FDA as the first DPP4 inhibitor fφor the treatment of type ⅱ diabetes mellitus. The characteristics of this drug ar¥e that it can stimulate insulin secretion while reducing hunger without causing weight ga‌in. Hypoglycemia and edema will not occur, and it is suitable for diabetic pδatients with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceuδtical enterprise that is market-oriented and realizes industrial development through R×&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most important product"s for the treatment of arthritis. It is well tolerated and has a low incidence o★f side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three m↔ajor leukotriene receptor antagonists. In clinical application, it has gδood therapeutic effect on atopic asthma and other ty∏pes of bronchial asthma, and the market prospect is huge. In the major category of asthma drugs, le‌ukotriene receptor antagonists have the fastest growing ma✔rket share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmεaceutical enterprise that is market-oriented and reali☆zes industrial development through R&D innovation and technology transfo rmation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved b$y FDA for Alzheimer's disease in the United States. Its treat≤ment reaches the target dose and has low toxic and side effects. φIt has been widely recognized by our medical commun♠ity, and good tolerance is its biggest advantage. In October 1999, Done✘pezil was launched in China under the trade name "Aricept", which is the main σchemical drug against Alzheimer's disease. At present, CF DA has approved a number of domestic enterprises to produce donep™ezil preparations, the main dosage forms are tablets, capsules, dispersive tablets, oral disλintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers S£quibb/Pfizer), a direct oral factor Xa inhibitor, was approved" for use in the 27 EU member states. The world's first drug appro★ved to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or knee φreplacement. From June 2019 to June 2020, the annual sales of apixaban products ±overseas reached about $15.4 billion, with a year-on-year grow​th of nearly 32%, and the API consumption reached about 23,960 kg, with a year-on-yeaβr growth of about 28%. Compared with its main competitor, Rivaroxaban, ☆the drug's annual overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise> that is market-oriented and realizes industrial development through R&D innovation and techn‍ology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Gen★zyme. On December 29, 2004, it was approved by FDA for the treatment of ♣refractory or relapsed acute lymphoblastic leukemia (↓ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical e∞nterprise that is market-oriented and realizes industrial development through R&✔D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other™ services, E-mail: 2880705932@qq.com
Submit

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Lt&d.